keyword
MENU ▼
Read by QxMD icon Read
search

cefepime avibactam

keyword
https://www.readbyqxmd.com/read/29149337/mechanisms-leading-to-in-vivo-ceftolozane-tazobactam-resistance-development-during-the-treatment-of-infections-caused-by-mdr-pseudomonas-aeruginosa
#1
Pablo A Fraile-Ribot, Gabriel Cabot, Xavier Mulet, Leonor Periañez, M Luisa Martín-Pena, Carlos Juan, José L Pérez, Antonio Oliver
Objectives: Characterization of the mechanisms driving ceftolozane/tazobactam resistance development in 5 of 47 (10.6%) patients treated for MDR Pseudomonas aeruginosa infections in a Spanish hospital. Methods: Five pairs of ceftolozane/tazobactam-susceptible/resistant P. aeruginosa isolates were studied. MICs were determined by broth microdilution, clonal relatedness was assessed by MLST and resistance mechanisms were investigated by phenotypic and genotypic methods, including WGS...
November 14, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29133568/activity-of-ceftolozane-tazobactam-against-carbapenem-resistant-carbapenemase-non-producing-pseudomonas-aeruginosa-and-associated-resistance-mechanisms
#2
Yu Mi Wi, Kerryl E Greenwood-Quaintance, Audrey N Schuetz, Kwan Soo Ko, Kyong Ran Peck, Jae-Hoon Song, Robin Patel
Although carbapenems are effective for treating serious multidrug-resistant Pseudomonas aeruginosa infections, carbapenem-resistant P. aeruginosa (CRPA) is now being reported worldwide. Ceftolozane/tazobactam (C/T) demonstrates activity against many multidrug-resistant isolates. We evaluated the activity of C/T and compared its activity to that of ceftazidime/avibactam (C/A) using a well-characterized collection of carbapenemase non-producing CRPA isolates. Forty-two carbapenemase non-producing CRPA isolates from a previous study (Int J Antimicrob Agents 2012;40:168-72) were included...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28993338/activity-of-ceftolozane-tazobactam-and-ceftazidime-avibactam-against-beta-lactam-resistant-pseudomonas-aeruginosa-isolates
#3
Romney M Humphries, Janet A Hindler, Annie Wong-Beringer, Shelley A Miller
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) minimum inhibitory concentrations were evaluated for a collection of 309 beta-lactam resistant isolates of Pseudomonas aeruginosa recovered from three institutions in Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% to meropenem, 20.7% to piperacillin-tazobactam, 24.6% to ceftazidime and 25.9% to cefepime, 72.5% to C/T and 61.8% to CZA. Among C/T-resistant isolates, 9.1% were CZA-susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T...
October 9, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28767588/successful-ceftazidime-avibactam-treatment-of-mdr-kpc-positive-klebsiella-pneumoniae-infection-in-a-patient-with-traumatic-brain-injury-a-case-report
#4
Agnese Gugliandolo, Carla Caio, Maria Lina Mezzatesta, Carmela Rifici, Placido Bramanti, Stefania Stefani, Emanuela Mazzon
RATIONALE: Carbapenem-resistant Enterobacteriaceae infections are a serious health care problem, because of the high mortality. Carbapenem resistance is mainly caused by carbapenemases production, including Klebsiella pneumoniae carbapenemase (KPC). Ceftazidime-avibactam is a new cephalosporin/β-lactamase inhibitor combination for the treatment of complicated urinary, intra-abdominal infections, and nosocomial pneumonia caused by gram negative, or other serious gram-negative infections...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28748397/activity-of-the-novel-siderophore-cephalosporin-cefiderocol-against-multidrug-resistant-gram-negative-pathogens
#5
J Dobias, V Dénervaud-Tendon, L Poirel, P Nordmann
The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative isolates collected from hospitals worldwide were tested against cefiderocol and antibiotic comparators (ceftolozane-tazobactam [CT], meropenem [MEM], ceftazidime [CAZ], ceftazidime-avibactam [CZA], colistin [CST], aztreonam [ATM], amikacin [AMK], ciprofloxacin [CIP], cefepime [FEP], and tigecycline [TGC]) for their susceptibility...
December 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28369471/activity-of-cefiderocol-s-649266-against-carbapenem-resistant-gram-negative-bacteria-collected-from-inpatients-in-greek-hospitals
#6
Matthew E Falagas, Tilemachos Skalidis, Konstantinos Z Vardakas, Nicholas J Legakis
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28362938/the-use-of-noncarbapenem-%C3%AE-lactams-for-the-treatment-of-extended-spectrum-%C3%AE-lactamase-infections
#7
Pranita D Tamma, Jesus Rodriguez-Bano
The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae...
April 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28115350/antimicrobial-activities-of-ceftazidime-avibactam-and-comparator-agents-against-clinical-bacteria-isolated-from-patients-with-cancer
#8
Ray Hachem, Ruth Reitzel, Kenneth Rolston, Anne-Marie Chaftari, Issam Raad
A total of 521 unique clinical isolates from cancer patients with primarily (>90%) bloodstream infections were tested for susceptibility to ceftazidime-avibactam and comparators using broth microdilution methods. Ceftazidime-avibactam inhibited 97.8% of all Enterobacteriaceae (n = 321) at the susceptibility breakpoint of ≤8/4 μg/ml (there were 7 nonsusceptible strains). It was also active against Pseudomonas aeruginosa (91.7% isolates susceptible, n = 121), including many isolates not susceptible to meropenem, cefepime, ceftazidime, piperacillin-tazobactam, or other comparators...
April 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28031201/emergence-of-ceftazidime-avibactam-resistance-due-to-plasmid-borne-blakpc-3-mutations-during-treatment-of-carbapenem-resistant-klebsiella-pneumoniae-infections
#9
Ryan K Shields, Liang Chen, Shaoji Cheng, Kalyan D Chavda, Ellen G Press, Avin Snyder, Ruchi Pandey, Yohei Doi, Barry N Kreiswirth, M Hong Nguyen, Cornelius J Clancy
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment of CRE infections and identify resistance mechanisms. Ceftazidime-avibactam-resistant K. pneumoniae emerged in three patients after ceftazidime-avibactam treatment for 10 to 19 days. Whole-genome sequencing (WGS) of longitudinal ceftazidime-avibactam-susceptible and -resistant K...
March 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27939093/susceptibility-to-cephalosporin-combinations-and-aztreonam-avibactam-among-third-generation-cephalosporin-resistant-enterobacteriaceae-recovered-on-hospital-admission
#10
MULTICENTER STUDY
Alexander Mischnik, Philipp Baumert, Axel Hamprecht, Anna Rohde, Silke Peter, Susanne Feihl, Johannes Knobloch, Hanna Gölz, Axel Kola, Birgit Obermann, Christiane Querbach, Matthias Willmann, Friedemann Gebhardt, Evelina Tacconelli, Petra Gastmeier, Harald Seifert, Winfried V Kern
As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0...
February 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27895902/effect-of-%C3%AE-lactamase-inhibitors-on-in-vitro-activity-of-%C3%AE-lactam-antibiotics-against-burkholderia-cepacia-complex-species
#11
Annelien Everaert, Tom Coenye
BACKGROUND: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including a variety of β-lactam antibiotics, is frequently observed in Bcc strains. Resistance to β-lactams is most commonly mediated by efflux pumps, alterations in penicillin-binding proteins or the expression of β-lactamases. β-lactamase inhibitors are able to restore the in vitro activity of β-lactam molecules against a variety of Gram-negative species, but the effect of these inhibitors on the activity of β-lactam treatment against Bcc species is still poorly investigated...
2016: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/27818808/persistent-bacteremia-from-pseudomonas-aeruginosa-with-in-vitro-resistance-to-the-novel-antibiotics-ceftolozane-tazobactam-and-ceftazidime-avibactam
#12
Louie Mar Gangcuangco, Patricia Clark, Cynthia Stewart, Goran Miljkovic, Zane K Saul
Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant Pseudomonas aeruginosa. We present the first case of persistent P. aeruginosa bacteremia with in vitro resistance to these novel antimicrobials. A 68-year-old man with newly diagnosed follicular lymphoma was admitted to the medical intensive care unit for sepsis and right lower extremity cellulitis. The patient was placed empirically on vancomycin and piperacillin-tazobactam. Blood cultures from Day 1 of hospitalization grew P...
2016: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/27743202/updates-in-the-management-of-cephalosporin-resistant-gram-negative-bacteria
#13
REVIEW
Andre Arizpe, Kelly R Reveles, Shrina D Patel, Samuel L Aitken
Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenem-sparing alternatives has increased. Additionally, the availability of the novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27712137/an-update-on-the-management-of-urinary-tract-infections-in-the-era-of-antimicrobial-resistance
#14
REVIEW
Mazen S Bader, Mark Loeb, Annie A Brooks
Urinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria are a growing concern due to limited therapeutic options. Gram-negative bacteria, specifically Enterobacteriaceae, are common causes of both community-acquired and hospital acquired UTIs. These organisms can acquire genes that encode for multiple antibiotic resistance mechanisms, including extended-spectrum-lactamases (ESBLs), AmpC- β -lactamase, and carbapenemases. The assessment of suspected UTI includes identification of characteristic symptoms or signs, urinalysis, dipstick or microscopic tests, and urine culture if indicated...
March 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/26976862/evaluation-of-the-in-vitro-activity-of-ceftazidime-avibactam-and-ceftolozane-tazobactam-against-meropenem-resistant-pseudomonas-aeruginosa-isolates
#15
Deanna J Buehrle, Ryan K Shields, Liang Chen, Binghua Hao, Ellen G Press, Ammar Alkrouk, Brian A Potoski, Barry N Kreiswirth, Cornelius J Clancy, M Hong Nguyen
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints...
May 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/26552987/interactions-of-op0595-a-novel-triple-action-diazabicyclooctane-with-%C3%AE-lactams-against-op0595-resistant-enterobacteriaceae-mutants
#16
David M Livermore, Marina Warner, Shazad Mushtaq, Neil Woodford
OP0595 is a novel diazabicyclooctane which, like avibactam, inhibits class A and C β-lactamases. In addition, unlike avibactam, it has antibacterial activity, with MICs of 0.5 to 4 μg/ml for most members of the family Enterobacteriaceae, owing to inhibition of PBP2; moreover, it acts synergistically with PBP3-active β-lactams independently of β-lactamase inhibition, via an "enhancer effect." Enterobacteriaceae mutants stably resistant to 16 μg/ml OP0595 were selected on agar at frequencies of approximately 10(-7)...
November 9, 2015: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/26243291/empiric-therapy-for-hospital-acquired-gram-negative-complicated-intra-abdominal-infection-and-complicated-urinary-tract-infections-a-systematic-literature-review-of-current-and-emerging-treatment-options
#17
REVIEW
Yoav Golan
BACKGROUND: Empiric therapy for healthcare-associated infections remains challenging, especially with the continued development of Gram-negative organisms producing extended-spectrum β-lactamases (ESBLs) and the threat of multi-drug-resistant organisms. Current treatment options for resistant Gram-negative infections include carbapenems, tigecycline, piperacillin-tazobactam, cefepime, ceftazidime, and two recently approved therapies, ceftolozane-tazobactam and ceftazidime-avibactam. METHODS: This systematic literature review surveys the published clinical trial evidence available since 2000 in support of both current and emerging treatment options in the settings of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI)...
August 5, 2015: BMC Infectious Diseases
https://www.readbyqxmd.com/read/26162518/ceftazidime-avibactam-activity-when-tested-against-ceftazidime-nonsusceptible-citrobacter-spp-enterobacter-spp-serratia-marcescens-and-pseudomonas-aeruginosa-from-unites-states-medical-centers-2011-2014
#18
Helio S Sader, Mariana Castanheira, David J Farrell, Robert K Flamm, Ronald N Jones
A total of 6910 Enterobacteriaceae with inducible AmpC β-lactamases and 5328 Pseudomonas aeruginosa were collected from 71 US hospitals in 2011-2014 and were susceptibility tested using the reference broth microdilution method. Ceftazidime-avibactam demonstrated potent in vitro activity against all 3 Enterobacteriaceae genus groups evaluated, with MIC(50)/MIC(90) values of 0.12/0.5 μg/mL for Enterobacter spp. and Serratia marcescens and 0.12/0.25 μg/mL for Citrobacter spp. (99.8-99.9% susceptibility rates at ≤8 μg/mL)...
December 2015: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/25583732/in-vitro-antibacterial-activity-of-the-ceftazidime-avibactam-combination-against-enterobacteriaceae-including-strains-with-well-characterized-%C3%AE-lactamases
#19
Premavathy Levasseur, Anne-Marie Girard, Christine Miossec, John Pace, Ken Coleman
The novel β-lactamase inhibitor avibactam is a potent inhibitor of class A, class C, and some class D enzymes. The in vitro antibacterial activity of the ceftazidime-avibactam combination was determined for a collection of Enterobacteriaceae clinical isolates; this collection was enriched for resistant strains, including strains with characterized serine β-lactamases. The inhibitor was added either at fixed weight ratios to ceftazidime or at fixed concentrations, with the latter type of combination consistently resulting in greater potentiation of antibacterial activity...
April 2015: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/24940084/in-vitro-microdialysis-membrane-efficiency-of-broad-spectrum-antibiotics-in-combination-and-alone
#20
Shawn H MacVane, Seth T Housman, David P Nicolau
PURPOSE: Microdialysis is a valuable technique for studying the distribution of drugs into interstitial fluid, the target site for a pharmacologic effect. Due to incomplete equilibrium, retrodialysis is a method used to correct for relative recovery. The impact of two-drug combinations on probe recovery, however, remains unknown. METHODS: In vitro microdialysis was conducted for five antibiotics (avibactam, cefepime, ceftaroline, piperacillin-tazobactam, and vancomycin), representing three empiric antimicrobial regimens, to assess the impact of two-drug combinations on probe recovery...
2014: Clinical Pharmacology: Advances and Applications
keyword
keyword
62412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"